Work

Evaluation of Absolute Oral Bioavailability and Bioequivalence of Ribociclib, a Cyclin‐Dependent Kinase 4/6 Inhibitor, in Healthy Subjects

Year: 2020

Type: article

Source: Clinical Pharmacology in Drug Development

DOI: 10.1002/cpdd.853

Authors: Yan Ji, Ahmed M. Abdelhady, Tanay S. Samant, Shu Yang, Karen Rodriguez Lorenc

Institution: Novartis (United States)

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Novartis Pharmaceuticals Corporation

OpenAlex ID: W3045137922

FWCI: 0.89

Cites: 22

Cited by: 21

Related to: 10